Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
PubWeight™: 0.75‹?›
Published in Ann Oncol on April 01, 2017
Authors
J Liang1, N Bi1, S Wu2, M Chen3, C Lv4, L Zhao5, A Shi6, W Jiang7, Y Xu8, Z Zhou1, W Wang1, D Chen1, Z Hui1, J Lv1, H Zhang1, Q Feng1, Z Xiao1, X Wang1, L Liu1, T Zhang1, L Du9, W Chen10, Y Shyr9, W Yin1, J Li1, J He11, L Wang1
Author Affiliations
1: Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
2: Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou.
3: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou.
4: Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai.
5: Department of Radiation Oncology, Tianjin Cancer Hospital, Tianjin.
6: Department of Radiation Oncology, Beijing Cancer Hospital, Beijing.
7: Department of Radiation Oncology, Zhongshan Hospital Fudan University, Shanghai.
8: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
9: Center for Quantitative Sciences, Vanderbilt University, Nashville, USA.
10: Epidemic Research Laboratory.
11: Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.